News

Dr. Gilberto Lopes Joins Immorta Bio to Advance Cancer Research

Dr. Gilberto Lopes Joins Immorta Bio to Advance Cancer Research

Dr. Gilberto Lopes Brought on Board at Immorta Bio

Immorta Bio Inc., a pioneering longevity company focused on advancing scientific understanding of aging and its related diseases, has appointed Dr. Gilberto de Lima Lopes Jr., MD, MBA, FAMS to its Strategic Advisory Board. With a commitment to treating diseases of aging, Immorta Bio is set to revolutionize therapeutic strategies.

A Path to Clinical Trials for Innovative Immunotherapy

The company is actively collaborating with the FDA to propel its innovative senolytic immunotherapy, known as SenoVax™, into clinical trials specifically aimed at treating non-small cell lung cancer (NSCLC). This step signifies a significant progression towards developing groundbreaking therapies that target cancer effectively.

A Leader in Lung Cancer and Immunotherapy

Dr. Lopes has garnered international recognition for his extensive experience and leadership in lung cancer research and the emerging field of immuno-oncology. He has played a crucial role as the principal investigator of KEYNOTE-042, a pivotal trial that laid the groundwork for the FDA's first-line approval of pembrolizumab (Keytruda) for patients with PD-L1-positive advanced NSCLC. His career has fundamentally altered the landscape of lung cancer treatment, providing access to advanced immunotherapy to hundreds of thousands of patients globally.

Welcoming a Medical Pioneer

Boris N. Reznik, PhD, the Chairman and CEO of Immorta Bio, expressed enthusiasm about Dr. Lopes' appointment. "We are honored to welcome a medical pioneer who helped bring game-changing immunotherapy to lung cancer. With Dr. Lopes' guidance, we aim to deliver the next leap—senolytic immunotherapy—to patients who urgently need new options," Reznik stated. This collaboration signifies a bright future for Immorta Bio and the patients it serves.

Advancing SenoVax™ and Its Promise

Immorta Bio's lead program, SenoVax™, is a first-of-its-kind senolytic immunotherapy that aims to empower the immune system to selectively target and eliminate senescent cells. These aged, dysfunctional cells often accumulate in tumors, impeding effective immune response and treatment outcomes. Early preclinical studies reveal that SenoVax™ exhibits promising anti-tumor activity across a variety of solid tumor models, including those prevalent in lung, breast, glioma, and pancreatic cancers. The therapeutic also shows potential synergy when combined with traditional checkpoint inhibitors.

Creating a Synergistic Effect

Dr. Thomas E. Ichim, PhD, President and Chief Scientific Officer at Immorta Bio, emphasized the significance of SenoVax™ in modern oncology. He noted, "Our SenoVax™ program demonstrates that removing senescent cells can de-shield tumors and enable immune-mediated destruction. Beyond oncology, targeting senescence stands to restore youthful immune and regenerative function, a crucial part of our longevity vision." This focus on elder care dealings through scientific investigation expands the potential impacts of cancer therapies.

Dr. Lopes' Vision for the Future

Dr. Lopes expressed his enthusiasm about joining Immorta Bio, recognizing the opportunity to further explore the potentials of immunotherapy beyond traditional cancer treatments. This innovative approach highlights the foundational similarities between historical immunotherapies like pembrolizumab and the new direction aimed at boosting the immune response to tumors through senolytic pathways. "The concept behind SenoVax™—targeting senescent cells to enhance anti-tumor immunity—builds on the foundation established by checkpoint inhibitors like pembrolizumab. I am eager to help guide this innovative science toward patient care," said Dr. Lopes.

About Immorta Bio

Immorta Bio Inc. is a biotechnology leader with a dedication to longevity and the development of personalized therapies. The company's mission encompasses both SenoVax™—focusing on senolytic innovation—and StemCellRevivify™, which emphasizes personalized cellular rejuvenation and exosome technology. The company is gearing up for near-term clinical entry focused on advanced NSCLC treatments to push the boundaries of current therapeutic paradigms.

Frequently Asked Questions

What is the main focus of Immorta Bio?

Immorta Bio focuses on developing personalized therapies aimed at treating diseases of aging and addressing aging as a disease.

Who is Dr. Gilberto Lopes?

Dr. Gilberto Lopes is a renowned lung cancer expert and leader in immuno-oncology, known for his pivotal role in advancing checkpoint inhibitors.

What is SenoVax™?

SenoVax™ is Immorta Bio's first-in-class senolytic immunotherapy designed to target and eliminate senescent cells in tumors.

How does SenoVax™ work?

SenoVax™ works by training the immune system to selectively eliminate dysfunctional cells that contribute to tumor growth and resistance to therapy.

What is the significance of this appointment for Immorta Bio?

Dr. Lopes' appointment enhances Immorta Bio's leadership in lung cancer research while facilitating the development of next-generation immunotherapies.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

FDA Changes Shake Up Medtech Inspections Landscape

Updated Category News Views 124

Inspecting the Changing FDA Landscape If you’ve been treating FDA inspections like a ride down memory lane, it's time for a wake-up call. What F. David Rothkopf plans to tell the medical device teams at the MEDevice Silicon Valley event is simple: the game has changed. The FDA’s Quality Management System Regulation (QMSR) that kicked in on February 2, 2026, isn’t...

Continue Reading
A&G Management's Bold New Era with WPM Partnership

Updated Category News Views 122

Shaking Up Baltimore's Real Estate Scene Swapping up management partners can be a dicey game, but A&G Management seems to be pulling it off without a hitch. As of January 4, 2027, WPM Real Estate Management will take over the reins for more than 3,000 apartment homes scattered across Anne Arundel, Howard, and Baltimore counties. A new set of hands is stepping in for...

Continue Reading
Cheyenne Real Estate: Neighborhood Nuances and Choices

Updated Category News Views 144

Unearthing the Hidden Dynamics of Cheyenne's Real Estate You've got this picturesque vision in your head of Cheyenne, Wyoming—a sprawling cowboy town with its wild winds and wide-open spaces. But if you think all those neighborhoods are cut from the same cloth, you've got another thing coming. The real estate scene here is just as varied as the prairies stretching out...

Continue Reading
Sandals Foundation: Win a Trip, Boost Caribbean Education

Updated Category News Views 100

Sandals Resorts Stakes a Claim in Education While the rest of us are gravitating towards Black Friday deals and Cyber Monday sales, the Sandals Foundation decided to play a different game. This Giving Tuesday, they invite travelers not just to soak in the sun, but to spread a little of it around by supporting education for kids across the Caribbean. It's a classic example...

Continue Reading
Neil deGrasse Tyson Headlines HIMSS27 with Cosmic Insights

Updated Category News Views 188

celebrated science communicator, is set to close out the HIMSS27 conference with a keynote that's bound to leave a lasting impression. It's a fitting intersection of stars and stethoscopes, as the astrophysicist brings his expansive lens to the nitty-gritty of healthcare innovation. Splicing Science with Storytelling Folks, this ain't your standard healthcare gathering....

Continue Reading
Chicago Auto Show: Run & Explore Indoors This February

Updated Category News Views 130

Nobody’s thinking about running laps when they walk into a colossal auto show, but the Chicago Auto Show isn't letting the pedal ease off the gas. Swing by on February 14, folks, for something not typically seen on the floors of McCormick Place. Run participants have got one hour to log as many miles as they can on the 2.4-mile loop right inside the show. Why a Running...

Continue Reading
Gold Tumbles: Kinross Faces Class Action Lawsuit

Updated Category News Views 189

Digging Deep into Kinross's Legal Fallout Well, here's a doozy for those investing in the precious metal market. Kinross Gold Corporation (NYSE: KGC) finds itself knee-deep in legal muck. Investors who bought into the Canadian gold miner's promises might be scrambling, as a class action lawsuit has just been lobbed their way. The culprit? A hefty drop-off in their...

Continue Reading
Bacterial Breakthrough in Cancer Therapy: Game Changer?

Updated Category News Views 73

Blurring Lines Between Bugs and Biotech Well, wouldn't you know it, the eggheads over at Jeonbuk National University in South Korea are at it again, pushing the boundaries of what these little bacterial buggers can do. This time, they’ve had a crack at cancer therapy, using engineered Salmonella to pack a double punch against breast cancer in mice. Now, if that ain't...

Continue Reading
Local Bounti Expands: Acquires CEA Facilities

Updated Category News Views 63

Local Bounti's Strategic Acquisition Move Local Bounti's at it again, shaking up the indoor agriculture scene by snapping up some real estate from Revol Greens. We're talking 30 acres of primo certified-organic greenhouse space across Texas and Minnesota. And they’re picking these babies up right as they’re ready to grow, not like some flashy land grab. Digging into...

Continue Reading
S&P Global's Bold $2 Billion Debt Offering Details

Updated Category News Views 80

Drilling Down into S&P Global's Debt Move S&P Global's throwing its hat in the ring with a colossal $2 billion debt offering. Now, they aren't just setting it on the table — they're notably carving it up into three chunks. You’ve got $750 million at 5.600% that comes due in 2031, $600 million at 5.800% for 2034, and $650 million at a 6.000% rate maturing in 2036....

Continue Reading

Top 5 Most Recently Viewed Articles

Aurora Mobile's Upcoming Earnings Call: What to Expect

Updated Category News Views 155

Aurora Mobile's Upcoming Earnings Call Aurora Mobile Limited (NASDAQ: JG), a prominent player in customer engagement and marketing technology services in China, is set to announce its financial results for the third quarter of 2024 soon. The company will release its unaudited financial report on November 14, 2024, just before the opening of U.S. markets. Details of the...

Continue Reading
Accelerate Financial Technologies Announces New Cash Distributions

Updated Category News Views 122

Accelerate Financial Technologies Announces Cash Distributions Accelerate Financial Technologies Inc. has officially declared the upcoming cash distributions for its Exchange Traded Funds, a positive move aimed at enriching investor portfolios. These distributions, which are set to occur toward the end of 2025, reflect Accelerate's commitment to providing valuable returns...

Continue Reading
Oculis Holding AG: A Focus on Eye Care Innovations

Updated Category News Views 306

Oculis Holding AG Announces Upcoming Investor Conference Oculis Holding AG (NASDAQ: OCS), a cutting-edge biopharmaceutical company dedicated to enhancing eye health and making strides in ocular science, is gearing up for a noteworthy investor conference. The event promises to showcase the latest developments in their innovative research and product initiatives. Event...

Continue Reading
IPC Shares Buyback Program Results Highlight Strong Strategy

Updated Category News Views 154

International Petroleum Corporation's Recent Share Buyback International Petroleum Corporation (IPC or the Corporation) (TSX, Nasdaq Stockholm: IPCO) has successfully executed a significant share repurchase program, reinforcing its commitment to enhance shareholder value. From May 12 to 16, IPC repurchased a total of 146,900 common shares, marking a notable phase in its...

Continue Reading
Star Bulk Carriers Plans Upcoming Earnings Release and Call

Updated Category News Views 122

Upcoming Earnings Release for Star Bulk Carriers Star Bulk Carriers Corp., a prominent player in the global shipping industry, is gearing up to announce its financial results for the third quarter. The release is scheduled to take place after the market closes in New York City. Details of the Earnings Announcement The upcoming results, covering the period that ended on...

Continue Reading